1,203
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs

ORCID Icon, ORCID Icon, , , , , , , , ORCID Icon, & show all
Pages 787-794 | Received 20 Aug 2021, Accepted 25 Feb 2022, Published online: 16 Mar 2022

References

  • Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62(6):1576–1582.
  • Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.
  • Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581.
  • Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev. 2011;11(2):123–131.
  • Smolen J, Ledenwé R, Breedveld F. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–975.
  • Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625–639.
  • Ruffing V, Bingham C, Clifton O. Rheumatoid arthritis: treatment. Rheumatoid Arthritis; 2016 [accessed 2021 Aug 18]. https://www.hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/ra-treatment/
  • Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Heal Econ. 2008;8:49–60.
  • Escorpizo RBC, Bombardier C, Boonen A, et al. Worker productivity outcome measures in arthritis. J Rheumatol. 2007;34:1372–1380.
  • Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology. 2011;50:1083–1090.
  • Xavier RM, Zerbini CAF, Pollak DF, et al. Burden of rheumatoid arthritis on patients’ work productivity and quality of life. Adv Rheumatol (London, England). 2019;59:47.
  • da Rocha Castelar Pinheiro G, Khandker RK, Sato R, et al. Impact of rheumatoid arthritis on quality of life, work productivity and resource utilisation: an observational, cross-sectional study in Brazil. Clin Exp Rheumatol. 2013;31:334–340.
  • Salazar-Mejía CE, Galarza-Delgado DÁ, Colunga-Pedraza IJ, et al. Relationship between work productivity and clinical characteristics in Rheumatoid Arthritis. Reumatol Clin. 2019;15:327–332.
  • Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol. 2010;28:S32–40.
  • Hone D, Cheng A, Watson C, et al. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2013;65:1564–1572.
  • Takeuchi T, Nakajima R, Komatsu S, et al. Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study. Adv Ther. 2017;34:686–702.
  • Almoallim H, Kamil A. Rheumatoid arthritis: should we shift the focus from “treat to target” to “treat to work?” Clin Rheumatol. 2013;32:285–287.
  • Associates R. WPAI translations: (rheumatoid arthritis) v2.0. 2016 Mar 21. http://www.reillyassociates.net/WPAI_Translations-2.html
  • Braakman-Jansen LMA, Taal E, Kuper IH, et al. Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology. 2012;51:354–361.
  • Tang K, Beaton DE, Boonen A, et al. Measures of work disability and productivity: rheumatoid arthritis specific work productivity survey (WPS-RA), workplace activity limitations scale (WALS), work instability scale for rheumatoid arthritis (RA-WIS), work limitations questionnaire (WLQ), an. Arthritis Care Res (Hoboken). 2011;63(1):S337–49.
  • Associates R. WPAI Coding. 2016 Mar 21. http://www.reillyassociates.net/wpai_coding.html
  • Radominski SC, Cardiel MH, Citera G, et al. Tofacitinib, un inhibidor oral de la quinasa Janus, para el tratamiento de artritis reumatoide en pacientes de Latinoamérica: eficacia y seguridad de estudios fase 3 y de extensión a largo plazo. Reumatol Clin. 2017;13:201–209
  • Leggett S, van der Zee-neuen A, Boonen A, et al. Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative study. Rheumatology (Oxford). 2016;55:1364–1373.
  • Xavier RM, Zerbini CAF, Pollak DF, et al. Burden of rheumatoid arthritis on patients’ work productivity and quality of life. Adv Rheumatol. 2019;59:47
  • Almoallim H, Janoudi N, Alokaily F, et al. Achieving comprehensive remission or low disease activity in rheumatoid patients and its impact on workability – Saudi rheumatoid arthritis registry. Open Access Rheumatol Res Rev. 2019; 11: 89–95.
  • Symmons D, Mathers C, Pfleger B. The global burden of rheumatoid arthritis in the year 2000; 2006 [accessed 2021 Aug 20]. https://www.who.int/healthinfo/statistics/bod_rheumatoidarthritis.pdf
  • Zhang W, Bansback N, Boonen A, et al. Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12:R177.